A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease
Conclusions: SC HX575 in dialysis patients with renal anemia was therapeutically equivalent to the reference medicine in terms of maintaining stable Hb levels and safety.Am J Nephrol 2017;46:364 –370
Source: American Journal of Nephrology - Category: Neurology Source Type: research
More News: Anemia | Chronic Kidney Disease | Dialysis | Epogen | Hemodialysis | Kidney Transplant | Kidney Transplantation | Neurology | Peritoneal Dialysis | Procrit | Study | Transplant Surgery | Transplants | Urology & Nephrology